NexGel (NASDAQ:NXGL – Get Free Report) and Beta Bionics (NASDAQ:BBNX – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, earnings, profitability, dividends and valuation.
Valuation & Earnings
This table compares NexGel and Beta Bionics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| NexGel | $11.42 million | 0.17 | -$3.00 million | ($14.20) | -0.27 |
| Beta Bionics | $127.27 million | 7.01 | -$73.20 million | ($1.84) | -8.92 |
NexGel has higher earnings, but lower revenue than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than NexGel, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
2.2% of NexGel shares are held by institutional investors. 19.8% of NexGel shares are held by insiders. Comparatively, 5.3% of Beta Bionics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Analyst Ratings
This is a breakdown of current ratings and recommmendations for NexGel and Beta Bionics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| NexGel | 1 | 2 | 0 | 0 | 1.67 |
| Beta Bionics | 1 | 4 | 9 | 1 | 2.67 |
NexGel currently has a consensus price target of $40.00, suggesting a potential upside of 930.93%. Beta Bionics has a consensus price target of $23.69, suggesting a potential upside of 44.29%. Given NexGel’s higher probable upside, equities analysts clearly believe NexGel is more favorable than Beta Bionics.
Volatility & Risk
NexGel has a beta of 0.81, suggesting that its share price is 19% less volatile than the S&P 500. Comparatively, Beta Bionics has a beta of 3.44, suggesting that its share price is 244% more volatile than the S&P 500.
Profitability
This table compares NexGel and Beta Bionics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| NexGel | -51.26% | -121.18% | -41.15% |
| Beta Bionics | -65.31% | -27.33% | -24.28% |
Summary
Beta Bionics beats NexGel on 9 of the 15 factors compared between the two stocks.
About NexGel
NexGel, Inc. (NASDAQ:NXGL) develops and manufactures high-water-content hydrogel products for medical, consumer and other specialized applications. The company uses proprietary formulations and electron-beam processing to produce flexible, skin-compatible products designed to retain moisture and provide cooling, cushioning or conductive properties. Its product applications include wound care, burn and surgical care, pain management, medical diagnostics and personal wellness. NexGel supplies hydrogel sheets, patches and related components used in products such as wound dressings, therapeutic pads and medical electrodes.
About Beta Bionics
Beta Bionics, Inc. develops medical technology for people with insulin-dependent diabetes. Its main product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to help manage blood glucose levels with less manual adjustment by users. The iLet system combines an insulin pump with dosing software that works with a continuous glucose monitor. Rather than requiring users to enter detailed insulin settings, it is initialized using the user’s body weight and adjusts insulin delivery based on glucose readings.
Receive News & Ratings for NexGel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NexGel and related companies with MarketBeat.com's FREE daily email newsletter.
